These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
91 related articles for article (PubMed ID: 6758114)
1. [Acipimox treatment of hyperlipidemia type II]. Noseda G; Fragiacomo C; Cairoli R Schweiz Med Wochenschr; 1982 Dec; 112(49):1790-1. PubMed ID: 6758114 [TBL] [Abstract][Full Text] [Related]
2. Comparative study of acipimox and pravastatin in patients with combined hyperlipidemia. Fogari R; Marasi G; Vanasia A; Zoppi A; Lusardi P; Preti P Int J Clin Pharmacol Ther; 1997 Feb; 35(2):61-4. PubMed ID: 9147709 [TBL] [Abstract][Full Text] [Related]
3. A comparative study of policosanol Versus acipimox in patients with type II hypercholesterolemia. Alcocer L; Fernández L; Campos E; Más R Int J Tissue React; 1999; 21(3):85-92. PubMed ID: 10645516 [TBL] [Abstract][Full Text] [Related]
4. [Acipimox (Olbetam) as a secondary hypolipemic agent in combined hypertriglyceridemia and hyperlipidemia]. Yeshurun D; Hamood H; Morad N; Naschitz J Harefuah; 2000 Apr; 138(8):650-3, 710. PubMed ID: 10883206 [TBL] [Abstract][Full Text] [Related]
5. [A double-blind cross-over trial of a new hypolipidaemic drug (author's transl)]. Proto C; Quadri A; Ratti S; Levi GF; Prandini BD G Ital Cardiol; 1978; 8(7):743-51. PubMed ID: 355033 [TBL] [Abstract][Full Text] [Related]
6. [Therapy of hyperlipidemia. Clinical experience with clinofibrate]. Avellone G; Di Garbo V; Strano A Clin Ter; 1989 Apr; 129(1):25-9. PubMed ID: 2525449 [TBL] [Abstract][Full Text] [Related]
7. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial. Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476 [TBL] [Abstract][Full Text] [Related]
8. The additional effects of acipimox to simvastatin in the treatment of combined hyperlipidaemia. Hoogerbrugge N; Jansen H; De Heide L; Zillikens MC; Deckers JW; Birkenhäger JC J Intern Med; 1997 Feb; 241(2):151-5. PubMed ID: 9077372 [TBL] [Abstract][Full Text] [Related]
9. Lipid-lowering effect of the new drugs eniclobrate and beclobrate in patients with hyperlipidemia type II a and type II b. Najemnik C; Lageder H; Regal H; Irsigler K Arzneimittelforschung; 1981; 31(12):2168-9. PubMed ID: 7037012 [TBL] [Abstract][Full Text] [Related]
10. [Multicenter clinical, double blind, and randomized study to assess the effectiveness and safety of binifibrate versus gemfibrozil in type IIa, IIb, and IV hyperlipidemia]. Corominas Vilardell A; de Oya Otero M; Escobar Jiménez F; Anguera Vila A; Ariño Armengol B An Med Interna; 1993 Nov; 10(11):537-41. PubMed ID: 8117868 [TBL] [Abstract][Full Text] [Related]
11. The additional effects of acipimox to simvastatin in the treatment of combined hyperlipidaemia. Hoogerbrugge N; Jansen H; De Heide L; Zillikens MC; Deckers JW; Birkenhäger JC J Intern Med; 1998 May; 243(5):151-6. PubMed ID: 9651568 [TBL] [Abstract][Full Text] [Related]
12. [Treatment of primary hyperlipidemia with 5-methylpyrazinecarboxylic acid (acipimox)]. Quintão EC; de Castilho LN Arq Bras Cardiol; 1985 Jan; 44(1):37-40. PubMed ID: 4062591 [No Abstract] [Full Text] [Related]
13. Metabolism of apolipoprotein B in primary moderate hypercholesterolaemia: effects of acipimox and cholestyramine therapy. Gaw A; Packard CJ; Lindsay GM; Collins SM; Lorimer AR; Shepherd J Eur J Med Res; 1995 Oct; 1(1):38-48. PubMed ID: 9392692 [TBL] [Abstract][Full Text] [Related]
14. [Acipimox in primary hyperlipidemias: safety and efficacy evaluated in six months]. Davidoff P; Ruiz F; Varas MA; García de los Ríos M; Silva MA; González G; Tapia JC Rev Med Chil; 1991 Oct; 119(10):1140-6. PubMed ID: 1845208 [TBL] [Abstract][Full Text] [Related]
15. [Clinical effectiveness of acipimox and fenofibrate in patients with hyperlipoproteinemia type II]. Chojnowska-Jezierska J; Jabłoński S; Tkaczewski W Wiad Lek; 1993 May; 46(9-10):332-6. PubMed ID: 8236987 [TBL] [Abstract][Full Text] [Related]
16. [Personal experience with the hypolipidemic agent Olbetam-Acipimox in hyperlipoproteinemia associated with type II diabetes]. Rajecová E; Kréze A; Klimes I; Cvrkalová A; Lacko A; Langrová H; Hanzen E Cas Lek Cesk; 1991 Nov; 130(22-23):661-3. PubMed ID: 1786587 [TBL] [Abstract][Full Text] [Related]
17. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Kuivenhoven JA; de Grooth GJ; Kawamura H; Klerkx AH; Wilhelm F; Trip MD; Kastelein JJ Am J Cardiol; 2005 May; 95(9):1085-8. PubMed ID: 15842977 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. McCrindle BW; Ose L; Marais AD J Pediatr; 2003 Jul; 143(1):74-80. PubMed ID: 12915827 [TBL] [Abstract][Full Text] [Related]
19. The effect of simvastatin on HDL cholesterol in hyperlipidemic patients. Evidence of a relationship with the changes in serum triglyceride level. Branchi A; Rovellini A; Fiorenza AM; Maraffi F; Gandini R; Sommariva D Int J Clin Pharmacol Ther; 1996 Sep; 34(9):384-9. PubMed ID: 8880287 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia. Farnier M; Roth E; Gil-Extremera B; Mendez GF; Macdonell G; Hamlin C; Perevozskaya I; Davies MJ; Kush D; Mitchel YB; Am Heart J; 2007 Feb; 153(2):335.e1-8. PubMed ID: 17239698 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]